AstraZeneca Share Price (AZN)

4,318.50 -150.00 (-3.36%) delayed: 11:58AM GMT
Bid price 4,318.50 Open price 4,450.00
Ask price 4,321.00 Prev close 4,318.50
High price 4,509.98 Spread 0.06%
Low price 4,297.50 Volume 5,682,885

Register now for FREE live AstraZeneca share prices, AstraZeneca stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get AstraZeneca Level 2 Data, indepth research tools and investor commentary for AstraZeneca (AZN) and other London Stock Exchange equities.

AstraZeneca Share Price Chart

Advanced Charts >>

Register now for FREE AstraZeneca share price charts

AstraZeneca Share Price Information

Name AstraZeneca Epic AZN
Sector Pharmaceuticals & Biotechnology ISIN GB0009895292
Activites One of the world's leading pharmaceutical companies. Index FTSE 100

AstraZeneca Key Numbers

Latest Share Price (p) 4,318.50 Net Gearing (%) 58.84
Market Capitalisation (£m) 56,536.78 Gross Gearing (%) 69.22
Shares in issue (m) 1,265.23 Debt Ratio 59.10
P/E Ratio 20.04 Debt-to-Equity Ratio 0.64
Total dividends per share (p) 188.50 Assets / Equity Ratio 3.25
Dividend Yield (%) 4.47 Price to book value 3.05
Dividend cover (x) 2.79 ROCE (%) 6.78
Earning per share (p) 223.00 EPS Growth (%) 127.55
52 week high / low 5,505.00 / 3,680.00 DPS Growth (%) 5.84

AstraZeneca Director Deals

Dec.Date Type Director Pos No. of Shares
16/12/2016 TOUT Pascal Soriot CEO 59,951
01/11/2016 BUY Graham Chipchase NED 100
01/08/2016 TIN Marc Dunoyer FD 43,730
14/06/2016 TIN Pascal Soriot CEO 84,316
26/02/2016 TIN Pascal Soriot CEO 3,039

More AstraZeneca Director Deals >>

AstraZeneca Company News

07:16 17/01/2017

AZ expands lung cancer programme

AstraZeneca has issued an update on its immuno-oncology late-stage clinical development programme in first-line non-small cell lung cancer, including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and...

07:04 17/01/2017

FLASH: AZ expands lung cancer programme

Story provided by StockMarketWire.com

07:00 17/01/2017

AZ 1st-line lung cancer immuno-oncology programme

RNS Number : 3289U AstraZeneca PLC 17 January 2017   17 January 2017 07:00   ASTRAZENECA EXPANDS 1ST-LINE LUNG CANCER IMMUNO-ONCOLOGY PROGRAMME OPPORTUNITIES   Refined endpoints and statistical analysis plan in the Phase III MYSTIC trial   China...

More AstraZeneca Company News >>

Register now for FREE AstraZeneca company news

AstraZeneca Share Price Discussions

5 months ago

Any views on Astrazeneca (AZN)

Got a good line of products, but the share price seem to go down , could it be due to the weak us dollar.

more than 1 year ago

Two Peaches!!!! (AZN)

(option stock price + price paid) (stock option sell price chnge on day for option) LOG MAY 280 PUT 23+6 263 24 AZN MAY 2600 PUT 104+25 2548 118 THESE WILL MOVE QUICKLY!

more than 1 year ago

FTSE signals (AZN)

FTSE 100 :4410.7+25 @16:36 MAIN S/R 4518 TARGET 4375/1 MINI S/R 4446 TARGET 4357/1 VOL 2850 YIELD 3.26 BAROMETER 32 LONG FTSE FUTURE (JUN 04) ARE @ 4423, 13 POINTS ABOVE CASH AND 1.5 ABOVE FAIR VALUE OF +11.5 DOW @ 10396+39 @ 17:00 (PUT YOUR SHORTS ON!!)

Register now for FREE AstraZeneca share price discussions